Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients

Clinical Trial of Safety, Pharmacodynamics and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Primary Treatment of HIV-infected Patients

A Randomized, Double-Blind, Parallel-Group, Exploratory Clinical Study to Evaluate the Safety, Pharmacodynamic Effects, and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Treatment-Naive HIV-Infected Individuals

Study Overview

• Status: Completed
• Conditions: Hiv
• Intervention / Treatment: Drug: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.

Detailed Description

This is a randomized, double-blind, parallelize-designed, multicenter, exploratory clinical study to evaluate the safety, PD, and PK profile of multiple subcutaneous injections of LP-98 in HIV-infected individuals who have not received antiviral therapy.

This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

The study included screening period (D-28~D-1), treatment period (D1-D57), and follow-up period (D58~D71).

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• China
  • Henan
    • Zhengzhou, Henan, China
      • Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Voluntarily participate in the study and obtain informed consent prior to any study-related evaluation;
2. Aged 18-65 years at the time of the screening visit (including the cut-off), male or female;
3. At the time of screening visit, the weight of male subjects is not less than 50 kg and that of female subjects is not less than 45 kg;
4. Plasma HIV RNA level ≥1000 copies /mL, CD4+T lymphocyte count ≥200 /μL;
5. For female subjects: Only subjects with no reproductive potential were included, including surgical sterilization at least 6 weeks prior to the screening visit (documented hysterectomy or bilateral oopectomies), and menopause ≥12 months prior to the screening visit (menopause confirmed by follicle stimulating hormone (FSH) level ≥40IU/L);
6. For male subjects with fertile female partners, consent must be given to the use of non-drug contraception for 14 days prior to dosing, during the study period, and for 3 months after dosing. Male subjects are not allowed to donate sperm during this period;
7. Be willing to comply with visits, study treatments, laboratory tests, and other study-related procedures and requirements as specified in the study protocol.

Exclusion Criteria:

1. is allergic to the investigational drug product or its excipients, or has a history of severe allergy (including any food allergy or drug allergy);
2. have received antiviral therapy (ART), or been vaccinated against HIV;
3. Have a history of serious illness or other serious chronic diseases;
4. Have a history of mental illness, or have a family history of mental illness;
5. any of the following conditions exist: i. Unexplained persistent irregular fever above 38 °C within 1 month before or during the screening period; ii. Persistent diarrhea (more than 3 stools/day) within 1 month before or during the screening period; iii. Severe infection, opportunistic infection, or sepsis in the 6 months prior to or during the screening period;
6. Hepatitis B surface antigen (HBsAg) positive, or hepatitis C antibody (HCV-Ab) positive;
7. The 12-lead ECG was abnormal and clinically significant during screening, such as QTcF interval (Fridericia correction) > 450 ms in male and > 470 ms in female;
8. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 1.5 times ULN, or total bilirubin > 1.5 times ULN during screening;
9. Serum creatinine clearance (Ccr) at screening was < 60 mL/min (calculated according to Cockcroft-Gault formula);
10. A known or suspected history of drug abuse (morphine, methamphetamine, ketamine, dimethylene dioxyamphetamine, THC, cocaine), or a positive baseline drug screening test;
11. Heavy drinking in the year before screening (drinking more than 14 standard units per week, 1 standard unit containing 14 g of alcohol, such as 5% beer 360 ml, 40% spirits 45 ml, 12% wine 120 ml); Or fail to comply with the no-alcohol policy for the duration of the study;
12. Smoking more than 5 cigarettes per day in the 3 months prior to screening, or failing to comply with the no-smoking policy during the study period;
13. have received any vaccine in the three months prior to screening, or plan to receive any vaccine during the study period;
14. received any investigational drug therapy or participated in any drug/investigational device trial within 3 months prior to dosing;
15. had undergone a major surgical procedure within 30 days prior to dosing or planned to undergo a major surgical procedure during the study period;
16. Those who have donated blood or lost blood ≥ 400 ml or received blood transfusion within 3 months before screening;
17. There are other circumstances that are not suitable for participation in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dose level(1.25mg); This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.	Drug: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.; This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
Experimental: Dose level(2.5mg); This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.	Drug: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.; This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
Experimental: Dose level(5mg); This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.	Drug: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.; This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
Experimental: Dose level(10mg); This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.	Drug: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.; This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes from baseline in respiration rate of Vital Signs.	Respiration rate in times / minute	Within 71 days after the first administration.
Changes from baseline in blood pressure of Vital Signs.	Blood pressure in mmHg	Within 71 days after the first administration.
Changes from baseline in Blood lactate of Laboratory Examination.	Changes of blood lactate will be recorded.	Within 71 days after the first administration.
Changes from baseline in body temperature of Vital Signs.	Body temperature in Celsius degree	Within 71 days after the first administration.
Changes from baseline in red blood cell count of Laboratory Examination.	Red blood cell count in whole blood is reported in the form of number.	Within 71 days after the first administration.
Changes from baseline in white blood cell count of Laboratory Examination.	White blood cell count in whole blood is reported in the form of number.	Within 71 days after the first administration.
Changes from baseline in neutrophil count of Laboratory Examination.	Neutrophil count in whole blood is reported in the form of number.	Within 71 days after the first administration.
Changes from baseline in lymphocyte count of Laboratory Examination.	Lymphocyte count in whole blood is reported in the form of number.	Within 71 days after the first administration.
Changes from baseline in platelet count of Laboratory Examination.	Platelet count in whole blood is reported in the form of number.	Within 71 days after the first administration.
Changes from baseline in hemoglobin of Laboratory Examination.	Changes of hemoglobin concentration（g/dL）in whole blood will be recorded.	Within 71 days after the first administration.
Changes from baseline in PT of Laboratory Examination.	Prothrombin time (PT) is a screening test for exogenous coagulation factors.	Within 71 days after the first administration.
Changes from baseline in INR of Laboratory Examination.	International standardized ratio (INR) is calculated from prothrombin time and international sensitivity index (ISI) of the reagent.	Within 71 days after the first administration.
Changes from baseline in APTT of Laboratory Examination.	Activated partial thromboplastin time (APTT) is a screening test for endogenous coagulation factors.	Within 71 days after the first administration.
Changes from baseline in total bilirubin of Laboratory Examination.	Changes of total bilirubin concentration (μmol/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in direct bilirubin of Laboratory Examination.	Changes of direct bilirubin concentration (μmol/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in ALT of Laboratory Examination.	Changes of ALT concentration (U/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in AST of Laboratory Examination.	Changes of AST concentration (U/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in total protein of Laboratory Examination.	Changes of total protein concentration (g/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in albumin of Laboratory Examination.	Changes of albumin concentration (g/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in urea of Laboratory Examination.	Changes of urea concentration (mmol/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in creatinine of Laboratory Examination.	Changes of creatinine concentration (μmol/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in uric acid of Laboratory Examination.	Changes of uric acid concentration (μmol/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in glucose of Laboratory Examination	Changes of glucose concentration (mmol/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in potassium of Laboratory Examination.	Changes of potassium concentration (mmol/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in sodium of Laboratory Examination.	Changes of sodium concentration (mmol/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in chlorine of Laboratory Examination.	Changes of chlorine concentration (mmol/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in urine specific gravity of Laboratory Examination.	Changes of urine specific gravity will be recorded.	Within 71 days after the first administration.
Changes from baseline in urine pH of Laboratory Examination.	Changes of urine pH value will be recorded.	Within 71 days after the first administration.
Changes from baseline in urine glucose of Laboratory Examination.	Changes of urine glucose will be examined by qualitative test (positive or negative).	Within 71 days after the first administration.
Changes from baseline in urine protein of Laboratory Examination.	Changes of urine protein will be examined by qualitative test (positive or negative).	Within 71 days after the first administration.
Changes from baseline in urine ketone body of Laboratory Examination.	Changes of urine ketone body will be examined by qualitative test (positive or negative).	Within 71 days after the first administration.
Changes from baseline in urine white blood cell of Laboratory Examination.	Changes of white blood cell in urine will be examined by qualitative test (positive or negative).	Within 71 days after the first administration.
Changes from baseline in urine bilirubin of Laboratory Examination.	Changes of urine bilirubin will be examined by qualitative test (positive or negative).	Within 71 days after the first administration.
Changes from baseline in urine occult blood of Laboratory Examination.	Changes of urine occult blood will be examined by qualitative test (positive or negative).	Within 71 days after the first administration.
Changes from baseline in Electrocardiogram.	The cardiac rhythm is showed in electrocardiogram in the form of continuous curve. Changes of this continuous curve will be recorded，To evaluate the incidence of abnormal electrocardiogram.	Within 71 days after the first administration.
Changes from baseline in CK of Laboratory Examination	Changes of CK concentration (U/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in CK-MB of Laboratory Examination	Changes of CK-MB concentration (ng/mL) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in LDH of Laboratory Examination	Changes of LDH concentration (U/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in ALP of Laboratory Examination	Changes of ALP concentration (U/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in Triglyceride of Laboratory Examination	Changes of Triglyceride concentration (mmol/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in CHOL of Laboratory Examination	Changes of CHOL concentration (mmol/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in TP of Laboratory Examination	Changes of TP concentration (g/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in ALB of Laboratory Examination	Changes of ALB concentration (g/L) in serum will be recorded.	Within 71 days after the first administration.
Changes from baseline in UA of Laboratory Examination	Changes of UA concentration (μmol/L) in serum will be recorded.	Within 71 days after the first administration.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes from baseline in Immunogenic blood collection of Laboratory Examination.	Changes of immunogenic blood collection will be recorded.The historical changes of test results (including positive rate and titer) of various indicators were counted.	Within 71 days after the first administration.
Changes from baseline in HIV viral load detection of Laboratory Examination.	Changes of HIV viral load detection will be recorded.	Within 71 days after the first administration.
Changes from baseline in CD4+T cell counts of Laboratory Examination.	Changes of CD4+T cell counts will be recorded.	Within 71 days after the first administration.

Collaborators and Investigators

• Sponsor: Shanxi Kangbao Biological Product Co., Ltd.
• Collaborators: Institute of Pathogen Biology, Beijing, China
• Investigators: Study Director: Qingxia Zhao, Doctor, Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)

Study record dates

Study Major Dates

• Study Start (Actual): September 2, 2024
• Primary Completion (Actual): January 10, 2025
• Study Completion (Actual): August 22, 2025

Study Registration Dates

• First Submitted: August 15, 2024
• First Submitted That Met QC Criteria: August 15, 2024
• First Posted (Actual): August 19, 2024

Study Record Updates

• Last Update Posted (Actual): May 11, 2026
• Last Update Submitted That Met QC Criteria: May 6, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Double-Blind; LP-98; Treatment-Naive HIV-Infected Individuals
• Additional Relevant MeSH Terms: Blood-Borne Infections; Urogenital Diseases; Genital Diseases; Immune System Diseases; Infections; RNA Virus Infections; Virus Diseases; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Slow Virus Diseases; HIV Infections; Acquired Immunodeficiency Syndrome
• Other Study ID Numbers: KB_LP-98_102

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No